FOSTER CITY, CA – Dec 3, 2020 – Dr. Michael Spinner, from Stanford University, Department of Medicine, Division of Oncology, will present at the 2020 Virtual ASH Annual Meeting an update to the recently published article in Blood Advances. This study used Notable Labs’ fully automated ex vivo drug sensitivity screening platform to test living tumor biopsies from patients with MDS and related myeloid neoplasms, and to identify correlations between clinical and genomic features and ex vivo drug sensitivity. Titled Correlating Clinical and Genomic Features with Ex Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms, this follow-up analysis involved patients evaluated at Stanford MDS Center between 2016-2020 with a diagnosis of MDS, MDS/MPN, or secondary AML. Ex vivo drug sensitivity screening defined three distinct patient clusters with differential sensitivity to numerous drug classes. Specific mutations were associated with greater ex vivo sensitivity to specific drug classes.
To hear more about this exciting study and more, visit the virtual poster hall on Monday, December 7th from 7:30 am-3:30 pm PST.
Our Notable team will be attending ASH this year. Schedule a meeting with our team and learn more about Notable’s proprietary automated, high-throughput, high-content, ex-vivo functional screening platform using living tumor biopsies.
Notable is redefining cancer treatment with a clinically validated AI platform that rapidly advances cancer drug development at a fraction of traditional costs. Notable’s approach combines AI with an automated lab to determine which drugs or combination of drugs will be most effective for specific types of cancers, enabling drug companies to recruit the right patients into clinical trials. The resulting high response rates in those trials can accelerate the process, eliminating much of the time and cost in later-stage trials, and helping to get drugs to market years faster at a lower cost to patients. Learn more at https://notablelabs.com/ or follow @notablelabs.